Last reviewed · How we verify
Tang-min Lin pill — Competitive Intelligence Brief
phase 3
Small molecule
Live · refreshed every 30 min
Target snapshot
Tang-min Lin pill (Tang-min Lin pill) — Guang'anmen Hospital of China Academy of Chinese Medical Sciences. Tang-min Lin pill's mechanism is not well-documented.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Tang-min Lin pill TARGET | Tang-min Lin pill | Guang'anmen Hospital of China Academy of Chinese Medical Sciences | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Tang-min Lin pill CI watch — RSS
- Tang-min Lin pill CI watch — Atom
- Tang-min Lin pill CI watch — JSON
- Tang-min Lin pill alone — RSS
Cite this brief
Drug Landscape (2026). Tang-min Lin pill — Competitive Intelligence Brief. https://druglandscape.com/ci/tang-min-lin-pill. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab